Merus N.V. and Partner Therapeutics, Inc. (PTx) announced on December 2, 2024, an exclusive license agreement for the U.S. commercialization of zenocutuzumab (Zeno) for NRG1 fusion-positive (NRG1+) cancer. PTx will assume full U.S. commercialization rights after a specified transition period.
Under the terms of the agreement, Merus will receive an upfront payment and is eligible for milestone payments. Additionally, Merus will receive high single-digit to low double-digit royalty payments based on annual net sales of Zeno in NRG1+ cancer in the U.S.
This partnership is a significant step for Merus, providing a clear commercialization pathway for Zeno in the U.S. market. It leverages PTx's oncology commercialization expertise and provides Merus with non-dilutive funding to support its broader pipeline development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.